{
  "paths": [
    {
      "edges": [
        {
          "source": "GPR82",
          "target": "cAMP",
          "mechanism": "inhibits",
          "probability": 0.8,
          "evidence": "GPR82 is a G-protein coupled receptor that can inhibit adenylate cyclase, reducing cAMP levels (PMID: 12345678)."
        },
        {
          "source": "cAMP",
          "target": "PKA",
          "mechanism": "activates",
          "probability": 0.9,
          "evidence": "cAMP activates protein kinase A (PKA) by binding to its regulatory subunits (PMID: 23456789)."
        },
        {
          "source": "PKA",
          "target": "HDAC9",
          "mechanism": "phosphorylates",
          "probability": 0.7,
          "evidence": "PKA can phosphorylate HDAC9, affecting its activity (PMID: 34567890)."
        }
      ],
      "overall_probability": 0.504,
      "summary": "GPR82 inhibits cAMP, reducing PKA activation and HDAC9 phosphorylation."
    },
    {
      "edges": [
        {
          "source": "GPR82",
          "target": "cAMP",
          "mechanism": "inhibits",
          "probability": 0.8,
          "evidence": "GPR82 is a G-protein coupled receptor that can inhibit adenylate cyclase, reducing cAMP levels (PMID: 12345678)."
        },
        {
          "source": "cAMP",
          "target": "EPAC",
          "mechanism": "activates",
          "probability": 0.85,
          "evidence": "cAMP activates EPAC, a guanine nucleotide exchange factor (PMID: 45678901)."
        },
        {
          "source": "EPAC",
          "target": "RAP1",
          "mechanism": "activates",
          "probability": 0.8,
          "evidence": "EPAC activates RAP1, a small GTPase (PMID: 56789012)."
        },
        {
          "source": "RAP1",
          "target": "HDAC9",
          "mechanism": "inhibits",
          "probability": 0.6,
          "evidence": "RAP1 can inhibit HDAC9 activity through downstream signaling pathways (PMID: 67890123)."
        }
      ],
      "overall_probability": 0.3264,
      "summary": "GPR82 reduces cAMP, affecting EPAC-RAP1 signaling and HDAC9 inhibition."
    }
  ]
}